How Does Asciminib Compare With Other TKIs in Long-Term #CML-CP Care? Author(s)Russ Conroy Fact checked by: Roman Fabbricatore @cmlnet @icmlf @jorgecortesmd cancernetwork.com/view/how-d…

La mejora de la supervivencia no implica calidad de vida (eso nos preocupa a los pacientes. Todos los TKI generan toxicidad menor o mayor, y se acumula. No olvidar: efectos secundarios muy dispares entre distintos pacientes. @cmlnet @icmlf #CML #LMC isanidad.com/375901/la-mejor…

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of #asciminib as compared with #imatinib and #nilotinib nature.com/articles/s41375-0… @NatureMedicine @Nature @cmlnet @icmlf

Young Patients with CML Face Higher TKI Resistance: EHA 2026 @EMJHematology emjreviews.com/hematology/ne… @cmlnet @icmlf

What does it take to shape the future of hematology? EMJ Editorial Lead Helena is at Day 1 of @EHA_Hematology 2026, where Claire Harrison was honoured with the Lifetime Achievement Award for her contributions to the field. Helena also sat down with Harrison to discuss what the award means to her and where her research is heading next. Want to learn more? Follow EMJ for daily insights straight from congress: hubs.la/Q04lbwfW0 #EHA2026

Con Eva Mingot, también miembro de la junta directiva de la @sehh_es, en #EHA2026 en Estocolmo, Suecia 🇸🇪

📢 We're hiring! The International CML Foundation is looking for a part-time Communications Manager (3 days/week, fully remote). Join our global team and help communicate the impact of our work improving outcomes for people with CML worldwide. Learn more: buff.ly/QkgbADK

📢 Your experience matters The iCMLf and I-BFM CML Working Group are developing the first recommendations for managing pediatric CML in LMICs. If you treat children with CML in LMICs, please share your insights through our global survey. Take the survey: buff.ly/HsNX7D3

📢 #EHA2026 update: first iCMLf CML session summary now available. Highlights: 🔹 3-year ASC4FIRST results with asciminib 🔹 Second TFR attempts (ReStop & NAUT) 🔹 Asciminib combination strategies 🔹 Early results with ELVN-001 Read the full summary here: buff.ly/gKw0yEO

CML updates from #EHA2026 Congress: Day 2 – Specialized Working Group Experts discussed learnings from international registries, the role of genomic profiling in identifying high-risk patients, and promising PDX models. Read the full summary here: buff.ly/syc3yYE

Avui presents al IV Congrés de persones amb càncer i familiars de Catalunya de @ContraCancerBCN . Un espai de trobada entre professionals, entitats, pacients i families al voltant del càncer. Un plaer aportar el nostre granet de sorra

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial ... prn.to/3RYALlw @Enliven_Tx @cmlnet @icmlf

Excited to get started with #EHA2026 with great representation by @ONealCancerUAB @uabmedicine. @End_myeloma @pankitvachhani @icmlf @ASH_hematology @BloodPortfolio

Great presentation by Jay Yang from @karmanoscancer on the ALERT CML study from the HJKC3 consortium. @icmlf @ONealCancerUAB @uabmedicine @ASH_hematology @BloodPortfolio

The disulfonic acid ANDS disrupts ANP32B-p53 interaction to suppress chronic myeloid leukemia #CML Yu-Sheng Wei, Fei-Yu Jin, …Guo-Qiang Chen" @cmlnet @icmlf nature.com/articles/s41467-0…

Quiero reconocer a quienes siguen adelante como pueden, a su propio ritmo, con sus alegrías y sus temores, con sus cicatrices visibles e invisibles. Y quiero agradecerles por compartir sus historias. Porque cada vez que alguien habla de su experiencia, ayuda a otras personas🧡🫰🏻

FDA Approves Orally Disintegrating #Nilotinib Tablets for Chronic Myeloid Leukemia #CML @cmlnet @icmlf Author(s)Chris Ryan Fact checked by: Ashling Wahner onclive.com/view/fda-approve…

Chronic Myeloid Leukemia Market is Projected to Grow Significantly by 2034 Owing to the Launch of Emerging Therapies | DelveInsight #CML @icmlf @cmlnet openpr.com/news/4540402/chro…

Cavhanza (#Nilotinib): FDA Approves Orally Disintegrating Tablet for Adults With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia #CML @cmlnet @icmlf webmd.com/drugs/updates/cavh…

RT @joancmarch: #Hantavirus: ciencia y #desmesura por @sminue donde critica la respuesta institucional y mediática al brote y considera #de…